Clinical Trial Update: CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial of CBP-201 for moderate-to-severe atopic dermatitis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• CBP-201

Snippet

Sponsor: Connect Biopharm LLC | Conditions: Atopic Dermatitis | Phase 3 | Status: WITHDRAWN